EUCTR2021-001707-32-NL进行中（未招募）1 期
ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial) - NIVOPTIMIZE-trial
Erasmus Medical Center Rotterdam0 个研究点目标入组 91 人开始时间: 2021年4月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 91
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age = 18 years
- •2.Advanced or metastatic melanoma or renal cell carcinoma
- •3.Current treatment with nivolumab in a 480 mg or 6mg/kg, 4 weekly scheme
- •4.Documented confirmed and ongoing CR, PR or SD according to RECIST v1.1
- •5.On treatment for at least 6 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 31
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •-Unable to draw blood for study purposes
- •-Patients willing to participate or already included in the SAFE-STOP trial
研究者
相似试验
进行中（未招募）
1 期
ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)CTIS2024-516718-39-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)34
招募中
不适用
ivolumab dose optimization during nivolumab therapy in melanoma patients after achieving a complete, partial or stable response (NIVOPTIMIZE-trial)10040900melanomaskin cancerNL-OMON54156Erasmus MC, Universitair Medisch Centrum Rotterdam34
已完成
2 期
ivolumab monotherapy in Rare tumor patients with mismatch repair deficiency biomarker: A phase II trialRare cancers with MSI-high or dMMRJPRN-jRCT2091220344Kan Yonemori, National Cancer Center Hospital15
进行中（未招募）
1 期
Golimumab dose variation to achieve response in Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2015-004724-62-IECD136
进行中（未招募）
1 期
An investigational immunotherapy study of Nivolumab combined with chemoradiotherapy , compared to chemoradiotherapy by itself, in patients with bladder cancer, not undergoing cystectomymuscle-invasive bladder cancer (MIBC)MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003447-34-GRHellenic Genitourinary Cancer Group (HGUCG)78